The purpose of this pilot study is to evaluate whether a combination of two drugs, dasatinib (D) and quercetin (Q) [D+Q], penetrate the brain using cerebrospinal fluid (CSF) in older adults with early Alzheimer's disease (AD). This combination of drug therapy has been shown to affect dying cells in humans with other chronic illnesses and in Alzheimer's mice models. The study team want to know if this combination of medications will reach the brain in order to evaluate if this intervention may be effective for treating AD symptoms in future studies. This is also known as a "proof of concept" study.
Floyd Jones
+1 (210) 450-3158
jonesfa@uthscsa.edu
Amy Saklad
(210) 567-8229
saklada@uthscsa.edu
Principal Investigator
Mitzi Gonzales
Mitzi Gonzales
(210) 450-9047
gonzalesm20@uthscsa.edu
Diana Jarbeau-may
(210) 617-5390
jarbeaumay@uthscsa.edu
Floyd Jones
+1 (210) 450-3158
jonesfa@uthscsa.edu
Amy Saklad
(210) 567-8229
saklada@uthscsa.edu
Arm | Description | Intervention |
---|---|---|
Intermittent D+Q | Senolytic treatment in 5 individuals with early AD to determine levels of drug that reach the central nervous system (CNS) by collecting cerebral spinal fluid (CSF), and begin collecting initial data on target engagement of senescent cells, AD-related markers, and AD-relevant outcomes for future trials. | Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles) Other names:
|